Corporate presentations Caribou Corporate Presentation June 11, 2026 Data presentations Categories AllCB-010 autoimmuneCB-011CB-012chRDNAIn vivovispa-cel Longer follow up data on dose escalation for CB-011 CaMMouflage phase 1 clinical trial, EHA 2026 oral presentation Long term durability data from the vispa-cel ANTLER phase 1 clinical trial, EHA 2026 oral presentation Clinical and translational data for CB-011 CaMMouflage Phase 1 clinical trial, Tandem Meetings 2026 presentation Translational data for vispa-cel ANTLER Phase 1 clinical trial, Tandem Meetings 2026 poster Clinical updates for vispa-cel (CB-010) and first clinical data for CB-011, company event 2025 CB-010 LBCL clinical data and KOL discussion, ASCO 2024 presentation CB-010 LBCL clinical data, ASCO 2024 poster CB-010 LBCL clinical case study, iwCAR-T presentation CB-010 LBCL clinical case study, LLM 2023 poster CB-010 B-NHL clinical data, July 2023 presentation Pagination Current page 1 Page 2 Next page › Last page »
Longer follow up data on dose escalation for CB-011 CaMMouflage phase 1 clinical trial, EHA 2026 oral presentation
Long term durability data from the vispa-cel ANTLER phase 1 clinical trial, EHA 2026 oral presentation
Clinical and translational data for CB-011 CaMMouflage Phase 1 clinical trial, Tandem Meetings 2026 presentation
